Device-Therapy in Chronic Heart Failure: Cardiac Contractility Modulation Versus Cardiac Resynchronization Therapy
ESC Heart Failure · 2025
DOI: 10.1002/ehf2.15067 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Goekhan Yuecel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidel…. Hauptthemen laut MEDLINE: Heart Failure, Cardiac Resynchronization Therapy, Myocardial Contraction, Stroke Volume. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: DZHK, Deutsche Forschungsgemeinschaft, Deutsches Zentrum für Herz-Kreislaufforschung.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
Cardiac implantable electrical devices such as cardiac resynchronization therapy with defibrillator (CRT-Ds) or cardiac contractility modulation (CCMs) are therapy options for patients with symptomatic heart failure (HF) and reduced left ventricular ejection fraction (LVEF) despite optimal medical treatment. As yet, a comparison between both devices has not been performed. Methods and results The Mannheim Cardiac Resynchronization Therapy Registry (MARACANA) and the Mannheim Cardiac Contractility Modulation Observational Study (MAINTAINED) included all patients who received CRTs or CCMs in our medical centre between 2012 and 2021. For the present analysis, we retrospectively compared patients provided with either CRT-Ds (n = 220) or CCMs with additional defibrillators (n = 105) regarding New York Heart Association classification (NYHA), LVEF, tricuspid annular plane systolic excursion (TAPSE), QRS-width and other HF modification aspects after 12 months. Before implantation, CCM patients presented with lower LVEF (23.6 ± 6.2 vs. 26.3 ± 6.5%) and worse NYHA (3.03 ± 0.47 vs. 2.81 ± 0.48, both P < 0.05), compared with CRT-D patients. Follow-up improvements in NYHA (2.43 ± 0.67 vs. 2.28 ± 0.72), LVEF (30.5 ± 10.7 vs. 35.2 ± 10.5%) and TAPSE (17.2 ± 5.2 vs. 17.1 ± 4.8 to 18.9 ± 3.4 vs. 17.3 ± 3.6 mm, each P < 0.05) were comparable. The intrinsic QRS-width was stable with CCM (109.1 ± 18 vs. 111.7 ± 19.7 ms, P > 0.05), while the paced QRS-width with CRT-D after 12 months was lower than intrinsic values at baseline (157.5 ± 16.5 vs. 139.2 ± 16 ms, P < 0.05). HF hospitalizations occurred more often for CCM than CRT-D patients (45.7 vs. 16.8%/patient years, odds ratio 4.2, P < 0.001).
Conclusions
Chronic heart failure patients could experience comparable 12-month improvements in functional status and ventricular reverse remodelling, with appropriately implanted CCMs and CRT-Ds. Differences in HF hospitalization rates may be due to the more advanced HF of CCM patients at implantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
- European Center for AngioScience (ECAS) and German Center for Cardiovascular Research (DZHK) Partner Site Heidelberg/Mannheim, Mannheim, Germany.
- Department of Medical Statistics and Biomathematics, Medical Faculty Mannheim, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany.
- Fifth Department of Medicine, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
- Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA.
ORCID-Profile: Goekhan Yuecel
Förderung
- DZHK
- Deutsche Forschungsgemeinschaft
- Deutsches Zentrum für Herz-Kreislaufforschung
Zitieren
APA
Yuecel, G., Gaasch, L., Kodeih, A., Hetjens, S., Yazdani, B., Pfleger, S., Duerschmied, D., Abraham, W. T., Akin, I., & Kuschyk, J. (2025). Device-Therapy in Chronic Heart Failure: Cardiac Contractility Modulation Versus Cardiac Resynchronization Therapy. ESC Heart Failure. https://doi.org/10.1002/ehf2.15067
Vancouver
Yuecel G, Gaasch L, Kodeih A, Hetjens S, Yazdani B, Pfleger S, et al. Device-Therapy in Chronic Heart Failure: Cardiac Contractility Modulation Versus Cardiac Resynchronization Therapy. ESC Heart Failure. 2025. doi:10.1002/ehf2.15067
BibTeX
@article{Yuecel2025,
author = {Yuecel, Goekhan and Gaasch, Leo and Kodeih, Abbass and Hetjens, Svetlana and Yazdani, Babak and Pfleger, Stefan and Duerschmied, Daniel and Abraham, William T and Akin, Ibrahim and Kuschyk, Juergen},
title = {Device-Therapy in Chronic Heart Failure: Cardiac Contractility Modulation Versus Cardiac Resynchronization Therapy},
journal = {ESC Heart Failure},
year = {2025},
doi = {10.1002/ehf2.15067}
}
EUVIMED